Study Design This study is a Phase I, open label trial of TEW-7197 in combination with standard doses of POM. The study will be conducted as a modified Fibonacci 3 + 3 dose escalation design to determine the MTD of TEW-7197 in combination with standard doses of POM. Patients will receive combination TEW-7197 /POM.